Tropion-Lung10 will combine dato-dxd with rilvegostomig, and focus on PD-L1 and TROP2 expression.

Two pancreatic cancer trials will read out this quarter, but after a string of failures with the project they look like a long shot.

One of the first human datasets concerning an ATM inhibitor shows glioblastoma’s intractability.

Early data with the group’s personalised project intrigue, but Transgene has a long road ahead.

First-in-human study initiations feature variations on well-trodden targets, plus a minor hiccup for OncoC4.

After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.